H. Akaike, A new look at the statistical model identification, IEEE Transactions on Automatic Control, vol.19, issue.6, pp.716-723, 1974.
DOI : 10.1109/TAC.1974.1100705

H. Athanassiou, M. Synodinou, E. Maragoudakis, M. Paraskevaidis, C. Verigos et al., Randomized Phase II Study of Temozolomide and Radiotherapy Compared With Radiotherapy Alone in Newly Diagnosed Glioblastoma Multiforme, Journal of Clinical Oncology, vol.23, issue.10, pp.2372-2377, 2005.
DOI : 10.1200/JCO.2005.00.331

T. Björk-eriksson, C. M. West, E. Karlsson, N. J. Slevin, S. E. Davidson et al., The in vitro radiosensitivity of human head and neck cancers, British Journal of Cancer, vol.77, issue.12, 1998.
DOI : 10.1038/bjc.1998.394

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg et al., Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies, British Journal of Cancer, vol.81, issue.6, pp.1022-1030, 1999.
DOI : 10.1038/sj.bjc.6690802

N. G. Burnet, S. J. Jefferies, R. J. Benson, D. P. Hunt, and F. P. Treasure, Years of life lost (YLL) from cancer is an important measure of population burden ??? and should be considered when allocating research funds, British Journal of Cancer, vol.6, issue.2, pp.241-245, 2005.
DOI : 10.1038/sj.bjc.6602321

N. G. Burnet, R. Jena, S. J. Jefferies, S. P. Stenning, and N. F. Kirkby, Mathematical Modelling of Survival of Glioblastoma Patients Suggests a Role for Radiotherapy Dose Escalation and Predicts Poorer Outcome After Delay to Start Treatment, Clinical Oncology, vol.18, issue.2, pp.93-103, 2006.
DOI : 10.1016/j.clon.2005.08.017

A. Chakravarti, M. G. Erkkinen, U. Nestler, R. Stupp, M. Mehta et al., Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms, Clinical Cancer Research, vol.12, issue.15, pp.4738-4746, 2006.
DOI : 10.1158/1078-0432.CCR-06-0596

J. L. Clarke, F. M. Iwamoto, J. Sul, K. Panageas, A. B. Lassman et al., Randomized phase III trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma, J. Clin. Oncol, issue.23, pp.27-3861, 2009.

L. M. Deangelis, Brain Tumors, New England Journal of Medicine, vol.344, issue.2, pp.114-123, 2001.
DOI : 10.1056/NEJM200101113440207

R. A. Dubay, P. G. Rose, D. M. O-'malley, A. D. Shalodi, A. Ludin et al., Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer, Gynecologic Oncology, vol.94, issue.1, pp.121-124, 2004.
DOI : 10.1016/j.ygyno.2004.03.034

S. E. Eikenberry, T. Sankar, M. C. Preul, E. J. Kostelich, C. J. Thalhauser et al., Virtual glioblastoma: growth, migration and treatment in a three-dimensional mathematical model, Cell Proliferation, vol.136, issue.4, pp.511-528, 2009.
DOI : 10.1111/j.1365-2184.2009.00613.x

J. F. Fowler, The linear-quadratic formula and progress in fractionated radiotherapy, The British Journal of Radiology, vol.62, issue.740, pp.679-94, 1989.
DOI : 10.1259/0007-1285-62-740-679

J. F. Fowler, Development of radiobiology for oncology???a personal view, Physics in Medicine and Biology, vol.51, issue.13, pp.263-286, 2006.
DOI : 10.1088/0031-9155/51/13/R16

E. Franceschi, A. Tosoni, V. Blatt, S. Bartolini, S. Rimondini et al., 2518 POSTER Prolonged maintenance chemotherapy with Temozolomide (TMZ) after concomitant treatment in newly diagnosed GBM: safety profile, European Journal of Cancer Supplements, vol.5, issue.4, pp.232-233, 2007.
DOI : 10.1016/S1359-6349(07)70921-7

T. Gorlia, M. J. Van-den-bent, M. E. Hegi, R. O. Mirimanoff, M. Weller et al., Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3, The Lancet Oncology, vol.9, issue.1, pp.26981-22981, 2008.
DOI : 10.1016/S1470-2045(07)70384-4

E. J. Hall and A. J. Giaccia, Radiobiology for the radiologist, 2006.

L. A. Hammond, J. R. Eckardt, S. D. Baker, S. G. Eckhardt, M. Dugan et al., Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies, Journal of Clinical Oncology, vol.17, issue.8, pp.17-2604, 1999.
DOI : 10.1200/JCO.1999.17.8.2604

B. Jones, L. T. Tan, and R. G. Dale, Derivation of the optimum dose per fraction from the linear quadratic model, The British Journal of Radiology, vol.68, issue.812, pp.894-902, 1995.
DOI : 10.1259/0007-1285-68-812-894

B. Jones and R. G. Dale, Mathematical Models of Tumour and Normal Tissue Response, Acta Oncologica, vol.10, issue.7, pp.883-893, 1999.
DOI : 10.3109/02841868409136037

B. Jones, R. G. Dale, C. Deehan, K. I. Hopkins, D. A. Morgan et al., The role of biologically effective dose (BED) in clinical oncology, Clin. Oncol, vol.13, issue.2, pp.71-81, 2001.

B. Jones and R. G. Dale, The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy, The British Journal of Radiology, vol.78, issue.934, pp.939-944, 2005.
DOI : 10.1259/bjr/40226390

B. Jones and P. Sanghera, Estimation of Radiobiologic Parameters and Equivalent Radiation Dose of Cytotoxic Chemotherapy in Malignant Glioma, International Journal of Radiation Oncology*Biology*Physics, vol.68, issue.2, pp.441-448, 2007.
DOI : 10.1016/j.ijrobp.2006.12.025

J. W. Kil, D. Cerna, W. E. Burgan, K. Beam, D. Carter et al., In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide, Clinical Cancer Research, vol.14, issue.3, pp.931-938, 2008.
DOI : 10.1158/1078-0432.CCR-07-1856

E. L. Kaplan and P. Meier, Nonparametric estimation from incomplete observations, 1958.
DOI : 10.1007/978-1-4612-4380-9_25

H. M. Keys, B. N. Bundy, F. B. Stehman, I. M. Laila, W. E. Chafe et al., Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma, New England Journal of Medicine, vol.340, issue.15, pp.340-1154, 1999.
DOI : 10.1056/NEJM199904153401503

N. F. Kirkby, Modelling and simulation of radiotherapy, Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms, vol.255, issue.1, pp.13-17, 2007.
DOI : 10.1016/j.nimb.2006.11.005

N. F. Kirkby, S. J. Jefferies, R. Jena, and N. G. Burnet, A mathematical model of the treatment and survival of patients with high-grade brain tumours, Journal of Theoretical Biology, vol.245, issue.1, pp.112-124, 2007.
DOI : 10.1016/j.jtbi.2006.09.007

P. Kleihues and W. K. Cavanee, Pathology & genetics of tumours of the nervous system. World Health Organisation classification of tumours, 2000.

D. A. Larson and W. M. Wara, Radiotherapy of primary malignant brain tumors, Seminars in Surgical Oncology, vol.17, issue.1, pp.34-42, 1998.
DOI : 10.1002/(SICI)1098-2388(199801/02)14:1<34::AID-SSU5>3.0.CO;2-3

E. S. Newlands, S. M. O-'reilly, M. G. Glaser, M. Bower, H. Evans et al., The charing cross hospital experience with temozolomide in patients with gliomas, European Journal of Cancer, vol.32, issue.13, pp.32-2236, 1996.
DOI : 10.1016/S0959-8049(96)00258-4

C. Nieder, M. P. Mehta, and R. Jalali, Combined Radio- and Chemotherapy of Brain Tumours in Adult Patients, Clinical Oncology, vol.21, issue.7, pp.515-524, 2009.
DOI : 10.1016/j.clon.2009.05.003

C. A. Perez and L. W. Brady, Principles and Practice of Radiation Oncology, Journal of Pediatric Hematology/Oncology, vol.21, issue.6, 1998.
DOI : 10.1097/00043426-199911000-00025

G. Powathil, M. Kohandel, S. Sivaloganathan, A. Oza, and M. Milosevic, Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy, Physics in Medicine and Biology, vol.52, issue.11, pp.52-3291, 2007.
DOI : 10.1088/0031-9155/52/11/023

X. S. Qi, C. J. Schultz, and X. A. Li, An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor, International Journal of Radiation Oncology*Biology*Physics, vol.64, issue.5, pp.1570-1580, 2006.
DOI : 10.1016/j.ijrobp.2005.12.022

P. G. Rose, B. N. Bundy, E. B. Watkins, J. T. Thigpen, G. Deppe et al., Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer, New England Journal of Medicine, vol.340, issue.15, pp.340-1144, 1999.
DOI : 10.1056/NEJM199904153401502

G. Schwarz, Estimating the Dimension of a Model, The Annals of Statistics, vol.6, issue.2, pp.461-464, 1978.
DOI : 10.1214/aos/1176344136

T. Sridhar, A. Gore, I. Boiangiu, D. Machin, and R. P. Symonds, Concomitant (without Adjuvant) Temozolomide and Radiation to Treat Glioblastoma: a Retrospective Study, Clinical Oncology, vol.21, issue.1, pp.19-22, 2009.
DOI : 10.1016/j.clon.2008.08.008

G. G. Steel and T. E. Wheldon, The radiation biology of paediatric tumours, Paediatric Oncology, 1991.

G. G. Steel, Basic clinical radiobiology, 2002.

M. F. Stevens, J. A. Hickman, R. Stone, N. W. Gibson, G. U. Baig et al., Antitumour Imidazotetrazines. 1. Synthesis and chemistry of 8- Carbamoyl-3-(2-chloroethyl)imidazol(3H)-one, a novel broadspectrum antitumor agent, J. Med. Chem, vol.51123, issue.27, pp.5-9, 1984.

M. F. Stevens, J. A. Hickman, S. P. Langdon, D. Chubb, L. Vickers et al., Antitumor activity and pharmacokinetics in mice of 8-Carbamoyl-3- methyl-imidazo, 81045; M & B 39831), a novel drug with potential as an alternative to decarbazine, pp.5-9, 1987.

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus concomitant and adjuvant temozolomide for gliobalstoma, N. Eng. J. Med, issue.10, pp.352-987, 2005.

R. Stupp, M. E. Hegi, W. P. Mason, M. J. Van-den-bent, M. J. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-466, 2009.
DOI : 10.1016/S1470-2045(09)70025-7

K. R. Swanson, E. C. Alvord, . Jr, and J. D. Murray, Quantifying efficacy of chemotherapy of brain tumors with homogeneous and heterogeneous drug delivery, 2002.

A. Tosoni, E. Franceschi, V. Blatt, S. Bartolini, E. Magrini et al., Temozolomide (TMZ) concomitant to radiotherapy (RT) plus 12 cycles of maintenance chemotherapy in newly diagnosed GBM: is more better? Eur, J. Canc, vol.5, issue.4, p.229, 2007.

P. Tracqui, G. C. Cruywagen, D. E. Woodward, G. T. Bartoo, J. D. Murray et al., A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth, Cell Proliferation, vol.32, issue.1, pp.17-31, 1995.
DOI : 10.1016/S0022-5193(87)80171-6

J. L. Villano, T. E. Seery, and L. R. Bressler, Temozolomide in malignant gliomas: current use and future targets, Cancer Chemotherapy and Pharmacology, vol.31, issue.4, pp.647-655, 2009.
DOI : 10.1007/s00280-009-1050-5

M. D. Walker, T. A. Strike, and G. E. Sheline, An analysis of dose-effect relationship in the radiotherapy of malignant gliomas, International Journal of Radiation Oncology*Biology*Physics, vol.5, issue.10, pp.1725-1731, 1979.
DOI : 10.1016/0360-3016(79)90553-4

L. Werko, Chapter 1: summary, Acta Oncol, vol.35, issue.S6, pp.9-23, 1996.

M. V. Williams, J. Denekamp, and J. F. Fowler, A review of ?/? ratios for experimental tumours: implications for clinical studies of altered fractionation Basic clinical radiobiology, 1985.